-
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
-
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
-
Ligand Pharma (LGND) PT Raised to $282 at Citi
-
Citi Adjusts Catalyst Call List
-
Citi Starts Ligand Pharma (LGND) at Buy
-
Ligand to Participate in September Investor Conferences
-
Ligand to Participate in Two Upcoming Investor Conferences
-
Top 10 News Items 6/18-6/22: Fed Slams the Door on QE3 But Extends Operation Twist; Greek Elections Take Help Ease Pressure; Moody's Downgrades Banks Across the Board
-
Loeb's Third Point Hedge Fund Gets Out of Citigroup (C), Shows New Stakes in CBS (CBS) and eBay (EBAY) Among Others
-
Loeb's Third Point Jumps Into BofA, Citi, Comcast, Yahoo!, Sells Out of Amedisys, Northern Trust (BAC) (C) (YHOO) (AMED)
-
Loeb's Third Point Q4 13F Breakdown: Ups Bets In Financials, Exits Large Pharma
-
Notable Analyst Rating Changes 1/22: BBY, AAP, ERIC, M Upgraded; DOX, MRVL, K, WYE Downgraded
-
Morning Movers 11/21: Citigroup (C) Bounces After Relentless Selling, Autodesk (ADSK) Lower On Results
-
Loeb's Third Point 13F; Shows New Stakes in BUD, C, CVS, MER, WEN, UST, Sells Out of MA
-
Pre-Open Movers 9/25: GE (GE) Lower On Profit Warning, Pilgrim's Pride (PPC) Sinks On Expected Large Loss and Covenant Triggers

